RFL Rafael Holdings Inc - Ordinary Shares - Class B

$RFL just an fyi, might get a ban for 30 days for calling out ST CEO for banning people that hurt his feelings. Long here and will ride through data readout.

$RFL Easy hold if you read and understand the science here. Easy to take a bearish stance if you assume all biotechs fail and don't look at the science.

$RFL Manipulation here. Very few shares are taking this down by .10 to .15, meanwhile, decent buys are not moving it. This tells you all you need to know.

$RFL Day 77 since last paitent 6/10 press release, 90 days is the outer time frame for data to be released, strap in it could come out in very short order, positive numbers on trial stock is 5-7

2-hours from market close and $RFL with a PHASE-3 readout in an ULTRA-RARE-DISEASE drug has less than $100K in overall market/trading interest. <$100K 😂 No, seriously, $100K. It’s almost worthy of the grief section at Hallmark Cards.

$RFL Where things stand. LPLV completed June 10, and the pre-NDA meeting is done. Both topline data and the NDA submission are expected in 2H calendar 2026, so we're inside the window but with no announcement. The stock has been range-bound all month. August has traded between $1.77 and $2.20, and RFL closed at $2.00 on August 3. That's a tight band with no directional conviction — consistent with a market waiting on a binary event rather than pricing one in. Year-to-date it's still up about 86%, most of which came on the LPLV run in June. A few things worth knowing that aren't the headline: The trial size is real. 94 patients across 27 sites in 13 countries, plus the 10-patient pediatric sub-study — described as the most comprehensive controlled pivotal study in NPC by patient size, footprint, and duration. Whatever the result, it won't be dismissed as underpowered.

$RFL If there’s a remaining pulse, the trading week of September 21 starts a strong volume and price move to the upside sans news. Just no way there isn’t a move ahead of Q4. Right?

Red is our destiny. We will not die or be denied. We are more than the sum of our broken hearts or spattered life goo. Most people want the eye candy of weight loss equities because that’s where the money is. So what! Is it not losing money that humbles our haughty hearts and poverty that lifts our eyes above the material quagmire of daily existence? No! We will not be attracted to the green life of deceptions, abundance, new cars and homes. We know the truth! If you want to escape material hell and enter into preparation for a new and better life of fleeting thoughts, fleeing friends and fries in your furniture,$RFL is one of the surest paths to get you there. Come fly with me.

$RFL Given your familiarity with NPC, I think the most important unknown is not whether cyclodextrin can mobilize cholesterol, but whether the trial demonstrates a sufficiently large clinical effect on disease progression after 96 weeks. That single number will likely determine whether RFL remains a $100M company or becomes a multi-billion-dollar rare disease company.

$RFL What we are dealing with. "Last patient completed the final visit" is not the same thing as "we have the data." Between those two points sits a long, unglamorous process, and Rafael's is bigger than most — 94 patients across 27 sites in 13 countries, plus a 10-patient pediatric sub-study. Every one of those sites needs close-out monitoring and source-data verification. Data queries get raised and resolved. Adverse events get coded. The statistical analysis plan gets locked down in final form. Only then does the database get locked, and only after the lock does anyone unblind and run the numbers. For a global Phase 3 of this size, two to four months from LPLV to topline is typical. June 10 to mid-September is right in the middle of that band.

$RFL assuming topline data is stat significant, and FDA approval is almost a guarantee, do we believe the market cap will take into consideration the potential for Alzheimer’s? I know we mentioned the trial was halted, but iam sure they were able to get some type of data at least a couple patients to have more than n=1

$RFL what if there was a day where somebody didn’t sell this off five minutes into the close, now that would be a miracle…..lol!!

$RFL here is a thought, what if we get the trial data for NP, and hopefully it’s good, and what if we also get data on the AD trial, which has been a little on the DL, and what if both are good!? There have been no updates on the AD trial, which should have also been finished by now.

$RFL There is no SEC rule requiring a company to disclose material information promptly just because it exists. Form 8-K has a specific list of triggering events, and clinical trial results aren't on it — companies file them voluntarily under Item 8.01, "Other Events." Regulation FD only prohibits selective disclosure: if they tell a big holder or an analyst, they have to tell everyone. It doesn't require them to tell anyone in the first place. A duty to speak generally arises only if they trade in their own securities while holding the information, if insiders trade, or if staying silent makes a prior public statement misleading. That last one is the real constraint here — they've given guidance, so guidance that goes stale eventually has to be addressed. As an NYSE-listed company, Rafael is also subject to the exchange's timely-disclosure policy, which asks listed companies to release material news promptly. It's a real obligation but a soft one in practice.

$RFL very nice long waiting for news ​watch $SMEV looking great nice volume we need to cross 0.012 for next leg up to 0.025 LONG breakout mode 0.01 200,000 shares for 2k Lottery ticket to 0.10 or 0.20

$RFL how long before NDA submission do biotech companies typically release topline results?